Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Neurocrine Biosciences Inc (NBIX) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance

Neurocrine Biosciences IncTrade
Tencent Music Entertainment Group - ADRTrade

Price performance (Past 24H)

Key statistics

Neurocrine Biosciences Inc vs Tencent Music Entertainment Group - ADR — how do they compare? Neurocrine Biosciences Inc trades at $156.99 (market cap $16.46B), while Tencent Music Entertainment Group - ADR trades at $8.38 (market cap $16.09B). The key difference: Neurocrine Biosciences Inc and Tencent Music Entertainment Group - ADR are close in size by market cap, and Tencent Music Entertainment Group - ADR pays a 2.75% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

NBIXTME
Market Cap
$16.46B$16.09B
Sector
HealthMedia
52-Week High
$185.50$26.36
52-Week Low
$123.10$8.16
Enterprise Value
$16.48B$14.05B
Dividend Yield
2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.

The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.

Tencent Music Entertainment Group - ADR

Tencent Music Entertainment (TME) is trading at $8.38, down 15.35% amid mixed Q2 2026 results that showed revenue growth but profit beat expectations. The stock faces bearish technical signals with oversold RSI conditions, while fundamentals remain strong with 33.6% net margin and attractive valuation at 10.29 P/E. Recent news highlights slowing operational growth and competitive pressures, though institutional activity shows mixed positioning with some funds increasing stakes while others reduce exposure.

TME presents a value opportunity with solid profitability and cash flow generation, but near-term headwinds include intensifying competition, AI-related copyright challenges, and slowing user growth. Analyst consensus leans neutral with 45.8% buy ratings, suggesting cautious optimism for long-term investors willing to navigate current volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX

About Tencent Music Entertainment Group - ADR

TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.

Read more on TME